Clinical trial
Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial
NCT07931807 is registered in ClinicalTrials.gov with The First Affiliated Hospital of University of Science and Technology of China as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 3, 1,395 participants (estimated). Lead sponsor The First Affiliated Hospital of University of Science and Technology of China; China. Primary measure: Functional Independence at 90 Days.
How it compares
263 similar trials: same condition (Ischemic Stroke) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial
- Lead sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- April 30, 2029
- Enrollment
- 1,395 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: acute ischemic stroke, medium vessel occlusion stroke (mevo)
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Arms
As registered; 3 arms.
| Arm | Type | Interventions |
|---|---|---|
| IVT Alone | Active comparator | Tenecteplase |
Show registry wordingParticipants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus. Endovascular treatment is not performed. | ||
| EVT Alone | Experimental | Endovascular Treatment |
Show registry wordingParticipants receive endovascular treatment without intravenous thrombolysis. | ||
| Bridging IVT Plus EVT | Experimental | Endovascular Treatment, Tenecteplase |
Show registry wordingParticipants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, followed immediately by endovascular treatment. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Functional Independence at 90 Days | 90 days after randomization (±14 days) |
Show registry wordingProportion of participants with a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, assessed by a blinded rater. The mRS ranges from 0 (no symptoms) to 6 (death). | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Tenecteplase
- US 5385732; expires June 2, 2014; assignee Genentech
Lead sponsor's other trials
The First Affiliated Hospital of University of Science and Technology of China, most recent start first.
+15 more trials See the organization page
Similar trials
Same condition (Ischemic Stroke) and phase, most recent start first.
+258 more trials See the condition page